These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9083337)

  • 1. A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.
    Jackson JK; Min W; Cruz TF; Cindric S; Arsenault L; Von Hoff DD; Degan D; Hunter WL; Burt HM
    Br J Cancer; 1997; 75(7):1014-20. PubMed ID: 9083337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
    Yuen VG; Orvig C; McNeill JH
    Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
    Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
    J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
    Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
    J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly with buthionine sulfoximine.
    Clark O; Park I; Di Florio A; Cichon AC; Rustin S; Jugov R; Maeshima R; Stoker AW
    Cancer Lett; 2015 Feb; 357(1):316-327. PubMed ID: 25444896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
    Yuen VG; Vera E; Battell ML; Li WM; McNeill JH
    Diabetes Res Clin Pract; 1999 Jan; 43(1):9-19. PubMed ID: 10199584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
    Yuen VG; Orvig C; McNeill JH
    Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
    Li M; Ding W; Baruah B; Crans DC; Wang R
    J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypoglycemic effects of bis(maltolato)oxovanadium administered by different routes upon diabetic rats].
    Zhong XY; Zhang H; Zhang X; Lv WL; Zhang Q
    Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 36(3):313-8. PubMed ID: 15205708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
    Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
    J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
    Peters KG; Davis MG; Howard BW; Pokross M; Rastogi V; Diven C; Greis KD; Eby-Wilkens E; Maier M; Evdokimov A; Soper S; Genbauffe F
    J Inorg Biochem; 2003 Aug; 96(2-3):321-30. PubMed ID: 12888267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
    Dabroś W; Dziga D; Kordowiak AM
    Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bis(maltolato)oxovanadium(IV) (BMOV) Attenuates Apoptosis in High Glucose-Treated Cardiac Cells and Diabetic Rat Hearts by Regulating the Unfolded Protein Responses (UPRs).
    Cong XQ; Piao MH; Li Y; Xie L; Liu Y
    Biol Trace Elem Res; 2016 Oct; 173(2):390-8. PubMed ID: 26983714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
    Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
    Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry.
    Nischwitz V; Davies JT; Marshall D; González M; Gómez Ariza JL; Goenaga-Infante H
    Metallomics; 2013 Dec; 5(12):1685-97. PubMed ID: 24136403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone.
    Bose S; Farah MA; Jung HC; Lee JH; Kim Y
    J Mol Endocrinol; 2007 Jun; 38(6):627-49. PubMed ID: 17556533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the Therapeutic Potential of Bis(Maltolato)OxoVanadium(IV): The Protective Role of Copper in Cellular Metabolism.
    Rivas-García L; López-Varela A; Quiles JL; Montes-Bayón M; Aranda P; Llopis J; Sánchez-González C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
    Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
    Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone-loaded poly(epsilon-caprolactone) intravitreal implants: a pilot study.
    Fialho SL; Behar-Cohen F; Silva-Cunha A
    Eur J Pharm Biopharm; 2008 Mar; 68(3):637-46. PubMed ID: 17851057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone.
    Dabroś W; Dziga D; Gryboś R; Kordowiak AM
    Pathol Res Pract; 2000; 196(8):561-8. PubMed ID: 10982019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.